TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12783052

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 40% 1-RM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 60% 1-RM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% 1-RM
Number of subjects: 13
Study: 10570099

Group type: EXPERIMENTAL
Intervention: Exercise during dialysis (pedalling on a cycle for 5-20 min at submaximal workload followed by 10 min rest, total 60 min exercise)
Number of subjects: 11
Study: 8735325

Group type: COMPARATOR
Intervention: Blood samples drawn from heparinized double-lumen Hickman catheters after discarding 5, 10, 15, 20, and 25 ml of blood.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Peripheral blood samples obtained simultaneously.
Number of subjects: 20
Study: 1836921

Group type: EXPERIMENTAL
Intervention: SmithKline Beecham's recombinant DNA (SB rDNA) vaccine (Engerix‐B) at its adult dose of 20 micrograms
Number of subjects: 48

Group type: COMPARATOR
Intervention: MSD rDNA vaccine
Number of subjects: 48
Study: 6407361

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (IVm) - 10 mg of morphine sulfate in 10 ml of saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural morphine (Em) - 10 mg of morphine sulfate in 10 ml of saline
Number of subjects: 10
Study: 31876670

Group type: EXPERIMENTAL
Intervention: Exergaming (EXE)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Balance (BAL)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cycling (CYC)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 68
Study: 31064897

Group type: EXPERIMENTAL
Intervention: Aggressive feeding regimen
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conservative feeding regimen
Number of subjects: 131
Study: 30223206

Group type: EXPERIMENTAL
Intervention: Introspection on craving and affect questions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral cues
Number of subjects: 0
Study: 26917660

Group type: EXPERIMENTAL
Intervention: GP triage
Number of subjects: 16711

Group type: EXPERIMENTAL
Intervention: Nurse triage
Number of subjects: 16711

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16711
Study: 25269764

Group type: EXPERIMENTAL
Intervention: Trigger Point Dry Needling (TrP DN)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Trigger Point Manual Therapy (TrP MT)
Number of subjects: 94
Study: 22103789

Group type: EXPERIMENTAL
Intervention: LESS surgery
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 25
Study: 19669016

Group type: EXPERIMENTAL
Intervention: Methadone (0.1 mg.kg‐1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Clonidine (2.0 (1/4)g.kg‐1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (NS)
Number of subjects: 126
Study: 17468473

Group type: EXPERIMENTAL
Intervention: icodextrin-based dialysate
Number of subjects: 17

Group type: COMPARATOR
Intervention: glucose-based dialysate
Number of subjects: 17
Study: 15376501

Group type: EXPERIMENTAL
Intervention: Vocal jitter in high-risk near-term suicidal patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glottal flow spectrum slope in high-risk near-term suicidal patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maximum likelihood classifier combining vocal jitter and glottal flow spectrum
Number of subjects: 30
Study: 11840802

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9824519

Group type: EXPERIMENTAL
Intervention: Physician and pharmacist teamwork approach
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 95
Study: 7523041

Group type: EXPERIMENTAL
Intervention: High vessel density in breast cancer patients
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low microvessel density in breast cancer patients
Number of subjects: 106

Group type: COMPARATOR
Intervention: Adenofibroma
Number of subjects: 106
Study: 2643046

Group type: EXPERIMENTAL
Intervention: Prednisone (45 mg per square meter of body-surface area, given on alternate days for six months)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 158
Study: 29575037

Group type: EXPERIMENTAL
Intervention: PMBL® Tablet
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 27056845

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (12 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 22
Study: 26335635

Group type: EXPERIMENTAL
Intervention: HIV nosode (30c potency pills), administered orally once a week for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (identical pills), administered orally once a week for 4 weeks
Number of subjects: 22
Study: 24096767

Group type: EXPERIMENTAL
Intervention: Frey procedure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pylorus-preserving pancreatoduodenectomy (PD)
Number of subjects: 64
Study: 21390330

Group type: EXPERIMENTAL
Intervention: Video communication with parent during separation episodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video communication with parent
Number of subjects: 0
Study: 18309940

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/d)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 197
Study: 16990386

Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg weekly for 4 weeks, followed by 900 mg one week later and then 900 mg every other week through week 26)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 87
Study: 15316551

Group type: EXPERIMENTAL
Intervention: Smooth stainless steel ultrasonic tips
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rotary preparations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrasonically prepared teeth
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sonic and ultrasonic devices
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Type of retrotip used
Number of subjects: 100
Study: 11349171

Group type: EXPERIMENTAL
Intervention: Cesarean delivery in HIV-seropositive women
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cesarean delivery in HIV-seronegative women (Control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Zidovudine use
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Major complications in HIV-seropositive women
Number of subjects: 86

Group type: COMPARATOR
Intervention: Major complications in HIV-seronegative women (Control)
Number of subjects: 86
Study: 9426795

Group type: EXPERIMENTAL
Intervention: Smoking cessation during the luteal phase
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Smoking cessation during the follicular phase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Smoking cessation (both groups)
Number of subjects: 40
Study: 8355458

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (Totamine, 6 to 8 mg/kg/min for 90 to 120 min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (Totamine) with perindoprilat (2 mg i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Perindoprilat (2 mg i.v.) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (Totamine)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Perindoprilat (2 mg i.v.)
Number of subjects: 18
Study: 2451409

Group type: EXPERIMENTAL
Intervention: High dose bunazosin (3 mg/day for the first week followed by 4.5 mg/day for the next three weeks)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Middle dose bunazosin (1.5 mg/day for the first week to 3.0 mg/day for the next three weeks)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Low dose bunazosin (0.15 mg/day for the first week to 1.5 mg/day for the next three weeks)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (0.125 mg/day for the entire four weeks)
Number of subjects: 205
Study: 30071871

Group type: EXPERIMENTAL
Intervention: LC‐Plasma (100 billion cells of heat‐killed LC‐Plasma per day for 13 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LC‐Plasma
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 27068158

Group type: EXPERIMENTAL
Intervention: Recreational football training (FT: n = 10)
Number of subjects: 27
Study: 24581059

Group type: EXPERIMENTAL
Intervention: Narrative messages
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Tailored messages
Number of subjects: 209

Group type: COMPARATOR
Intervention: Tailoring
Number of subjects: 209
Study: 23768813

Group type: EXPERIMENTAL
Intervention: Galantamine/CDP-choline
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 20595536

Group type: EXPERIMENTAL
Intervention: Infliximab and Methotrexate (INF-MTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo and Methotrexate (placebo-MTX)
Number of subjects: 20
Study: 18762060

Group type: EXPERIMENTAL
Intervention: Stuttering Measurement Assessment and Training (SMAAT) program training
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training (Control group)
Number of subjects: 20
Study: 16644023

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MX) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 20
Study: 12729289

Group type: EXPERIMENTAL
Intervention: Iron supplements 2 ng/kg/day (group IA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Iron syrup 6 mg/kg/day (group II)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (group IB)
Number of subjects: 150
Study: 11220944

Group type: EXPERIMENTAL
Intervention: Multimodal approach including spinal or spinal-epidural anesthesia, preoperative epidural opioid analgesics, and administration of drugs affecting NMDA receptors (ketamine, magnesium sulfate)
Number of subjects: 1912
Study: 8973523

Group type: EXPERIMENTAL
Intervention: Rhesus tetravalent rotavirus vaccine (RRV‐TV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serotype G1 monovalent rotavirus vaccine (RRV‐S1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-vaccination neutralizing antibody titers to Wa
Number of subjects: 0

Group type: COMPARATOR
Intervention: G1 breakthrough strains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control strains isolated from placebo recipients
Number of subjects: 0
Study: 1349112

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg twice daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: Parenteral combination antibiotics (amikacin 15 mg/kg daily, plus carbenicillin, cloxacillin, or piperacillin)
Number of subjects: 122
Study: 3840755

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Vagotomized patients)
Number of subjects: 22
Study: 30131229

Group type: EXPERIMENTAL
Intervention: Scheduled repetitive 24‐hour levosimendan infusions (LEVO) at tailored doses (0.05‐0.2 μg/kg/min)
Number of subjects: 185
Study: 27467714

Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day for 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 100
Study: 23914987

Group type: EXPERIMENTAL
Intervention: Psychoeducation plus Care Ambassador outreach
Number of subjects: 153

Group type: COMPARATOR
Intervention: Care Ambassador outreach
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 153
Study: 23187015

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit; used for a minimum of thirty minutes per day for five weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention (five weeks without any intervention)
Number of subjects: 18
Study: 20537626

Group type: EXPERIMENTAL
Intervention: Urinary hMG
Number of subjects: 122

Group type: COMPARATOR
Intervention: Recombinant FSH plus recombinant LH (Pergoveris)
Number of subjects: 122
Study: 18764999

Group type: EXPERIMENTAL
Intervention: 5 mg letrozole
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 16003671

Group type: EXPERIMENTAL
Intervention: Audio-biofeedback (ABF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (unaffected participants)
Number of subjects: 9
Study: 11856089

Group type: EXPERIMENTAL
Intervention: OAC250 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: OAC500 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: OTC group (omeprazole 20 mg, tinidazole 500 mg, clarithromycin 500 mg)
Number of subjects: 352
Study: 10102732

Group type: EXPERIMENTAL
Intervention: Head-down tilt with balanced traction (HDT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Horizontal bed rest (HBR)
Number of subjects: 6
Study: 7776513

Group type: EXPERIMENTAL
Intervention: Diltiazem 4 mcg.kg‐1.min‐1 constant infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem 2 mcg.kg‐1.min‐1 constant infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 24
Study: 2221490

Group type: EXPERIMENTAL
Intervention: 2 g vitamin C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 358479

Group type: EXPERIMENTAL
Intervention: BCG immunostimulation by scarifications (16 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BCG immunostimulation (10 treated patients)
Number of subjects: 29
Study: 30922154

Group type: EXPERIMENTAL
Intervention: PHYLLPRO™, 750 mg/day for 10 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (containing only excipient)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PHYLLPRO™
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PHYLLPRO™ and Placebo
Number of subjects: 15
Study: 27923485

Group type: EXPERIMENTAL
Intervention: Rigid plate fixation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Wire cerclage
Number of subjects: 236
Study: 25251043

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Laser ablation (LA)
Number of subjects: 140
Study: 23522182

Group type: EXPERIMENTAL
Intervention: AZD1656 (40-200 mg)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: AZD1656 (20-140 mg)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: AZD1656 (10-80 mg)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 21346213

Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PAS(25)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PAS(10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Contralateral hemisphere
Number of subjects: 10
Study: 19475523

Group type: EXPERIMENTAL
Intervention: Guided exercise programme
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 42
Study: 17826067

Group type: EXPERIMENTAL
Intervention: Single-fraction intraoperative radiotherapy (IORT) prescribed at 20 Gy to the surgical margins using soft x-rays (50 kV) delivered with the Intrabeam Photon Radiosurgery System.
Number of subjects: 779

Group type: COMPARATOR
Intervention: Whole-breast irradiation postoperatively.
Number of subjects: 779
Study: 11035612

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) once daily (400 mg/day, 250 mg/day if body weight <60 kg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Didanosine (ddI) twice daily (400 mg/day, 250 mg/day if body weight <60 kg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) once daily and twice daily
Number of subjects: 121
Study: 8840065

Group type: EXPERIMENTAL
Intervention: Nerve stimulator technique (NS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Loss of resistance technique (LOR)
Number of subjects: 46
Study: 1353489

Group type: EXPERIMENTAL
Intervention: Breast preservation
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Breast preservation with microscopically involved margins
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Overall local recurrences
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Overall regional recurrences
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Overall distant metastases
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: P-185 expression
Number of subjects: 1036
Study: 6496450

Group type: EXPERIMENTAL
Intervention: 3 micrograms doses of heat-inactivated hepatitis B surface antigen (HBsAg) at one-month intervals (trial A)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: 5 different dosages of the vaccine (trial B)
Number of subjects: 471
Study: 30215690

Group type: EXPERIMENTAL
Intervention: Teprotumumab, a monoclonal inhibitory antibody targeting IGF‐IR
Number of subjects: 0
Study: 29606129

Group type: EXPERIMENTAL
Intervention: Life Steps-Drug Use (LS-DU) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education intervention (control)
Number of subjects: 0
Study: 27749351

Group type: EXPERIMENTAL
Intervention: cFNB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: sFNB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LIA
Number of subjects: 120
Study: 25415159

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg vaginally)
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1362
Study: 22614110

Group type: EXPERIMENTAL
Intervention: 1-year gluten-free diet
Number of subjects: 222
Study: 20530110

Group type: EXPERIMENTAL
Intervention: TPN with heparin (0.5 IU/ml)
Number of subjects: 210

Group type: COMPARATOR
Intervention: TPN without heparin
Number of subjects: 210
Study: 18842911

Group type: EXPERIMENTAL
Intervention: Inhaled steroids treatment based on eNO and sEos levels
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional treatment based on symptoms and function
Number of subjects: 14
Study: 16080456

Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse (UAI) reported in 1999
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse (UAI) reported in 2002
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jackson Heights community
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: San Gabriel Valley community
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detroit community
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twin Cities community
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atlanta community
Number of subjects: 0

Group type: COMPARATOR
Intervention: San Diego community
Number of subjects: 0
Study: 15458106

Group type: EXPERIMENTAL
Intervention: Haptic feedback during suturing simulation
Number of subjects: 0
Study: 7723340

Group type: EXPERIMENTAL
Intervention: Allopurinol 200 mg intravenously 1 hour preoperatively
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no allopurinol)
Number of subjects: 33
Study: 2383382

Group type: EXPERIMENTAL
Intervention: Range of motion by the therapist
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Skate board
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overhead pulley
Number of subjects: 48
Study: 30882237

Group type: EXPERIMENTAL
Intervention: Maternal own milk (MOM) stimulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Water (sham) stimulus
Number of subjects: 36
Study: 28110424

Group type: EXPERIMENTAL
Intervention: Caffeine group (n = 15), coffee containing 222 mg of caffeine 2 hours before catheterization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-caffeine group (n = 15), instructed not to take caffeine for at least 12 hours before catheterization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeine group (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-caffeine group (n = 15)
Number of subjects: 30
Study: 27273884

Group type: EXPERIMENTAL
Intervention: Cycle Ergometry (CE) with 10 g protein/46 g carbohydrate drink (223 kcal)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combat rations supplemented with 1000 kcal/day from 20 g protein- or 48 g carbohydrate-based bars
Number of subjects: 113

Group type: COMPARATOR
Intervention: Combat rations alone (control)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Energy balance during military training
Number of subjects: 113
Study: 24518871

Group type: EXPERIMENTAL
Intervention: Gradual increase in ambient temperature (+4 K/h, ranging from 24 °C to 32 °C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gradual decrease in ambient temperature (‐4 K/h, ranging from 24 °C to 16 °C)
Number of subjects: 16
Study: 21173703

Group type: EXPERIMENTAL
Intervention: Static accommodation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Repeated accommodation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison of static vs repeated accommodation
Number of subjects: 33
Study: 20345030

Group type: EXPERIMENTAL
Intervention: Fixed-point spin reduction of spinal manipulation therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Dialectical prescription
Number of subjects: 168
Study: 18631903

Group type: EXPERIMENTAL
Intervention: MPT-OA plus standard treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 21
Study: 15993403

Group type: EXPERIMENTAL
Intervention: Illiterate individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Literate individuals
Number of subjects: 0
Study: 12362781

Group type: EXPERIMENTAL
Intervention: Micro-encapsulated ferrous fumarate (12.5 mg of elemental iron)
Number of subjects: 39
Study: 10355573

Group type: EXPERIMENTAL
Intervention: Further chemotherapy (3 courses of MIP: cisplatin 50 mg/m2, ifosfamide 3 g/m2, mitomycin C 6 mg/m2)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Chest irradiation (60 Gy; 2 Gy per fraction over six weeks)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Chest irradiation
Number of subjects: 115